Pages that link to "Q40158643"
Jump to navigation
Jump to search
The following pages link to Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract (Q40158643):
Displaying 50 items.
- Respiratory viruses other than influenza virus: impact and therapeutic advances (Q24655957) (← links)
- Anti-viral agents: potential utility in exacerbations of asthma (Q26853117) (← links)
- The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection (Q26864494) (← links)
- A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy (Q27314576) (← links)
- Genetically delivered antibody protects against West Nile virus (Q27485481) (← links)
- Structural basis of respiratory syncytial virus neutralization by motavizumab (Q27659146) (← links)
- Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F (Q27664797) (← links)
- Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus (Q27667750) (← links)
- Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (Q27667876) (← links)
- Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes (Q27668015) (← links)
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody (Q27677570) (← links)
- Proof of principle for epitope-focused vaccine design (Q27681593) (← links)
- Approved Antiviral Drugs over the Past 50 Years (Q27755387) (← links)
- Protein Crystallography in Vaccine Research and Development (Q28087528) (← links)
- Role of infections in the induction and development of asthma: genetic and inflammatory drivers (Q28389983) (← links)
- Bacteriophages and Their Immunological Applications against Infectious Threats. (Q30234522) (← links)
- Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy (Q30275229) (← links)
- Surface plasmon resonance for high-throughput ligand screening of membrane-bound proteins (Q30887281) (← links)
- In vitro affinity maturation of a natural human antibody overcomes a barrier to in vivo affinity maturation (Q31149925) (← links)
- A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo (Q33285591) (← links)
- Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discovery (Q33413784) (← links)
- A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection (Q33478019) (← links)
- Progress towards recombinant anti-infective antibodies (Q33568256) (← links)
- A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season (Q33595073) (← links)
- Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants (Q33723350) (← links)
- Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure (Q33744060) (← links)
- A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein (Q33775790) (← links)
- Pharmacologic advances in the treatment and prevention of respiratory syncytial virus (Q33776507) (← links)
- Nanohole-based surface plasmon resonance instruments with improved spectral resolution quantify a broad range of antibody-ligand binding kinetics. (Q34124085) (← links)
- Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range (Q34191108) (← links)
- Pharmacokinetics-Pharmacodynamics of a Respiratory Syncytial Virus Fusion Inhibitor in the Cotton Rat Model (Q34290125) (← links)
- Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites. (Q34291876) (← links)
- Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease (Q34330690) (← links)
- The infectious march: the complex interaction between microbes and the immune system in asthma (Q34356430) (← links)
- Respiratory viral infections in children with asthma: do they matter and can we prevent them? (Q34413913) (← links)
- Structure and function of respiratory syncytial virus surface glycoproteins. (Q34414405) (← links)
- A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism (Q34492100) (← links)
- Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo (Q34593860) (← links)
- Therapeutic targeting of respiratory syncytial virus G-protein. (Q34603346) (← links)
- Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab (Q34772752) (← links)
- In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability (Q34831383) (← links)
- Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool (Q34991715) (← links)
- The influence of antibody fragment format on phage display based affinity maturation of IgG. (Q35050036) (← links)
- Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease (Q35070176) (← links)
- pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling (Q35080330) (← links)
- Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge (Q35535626) (← links)
- Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4 (Q35556797) (← links)
- Antibody engineering for increased potency, breadth and half-life (Q35575206) (← links)
- Emerging paramyxoviruses: molecular mechanisms and antiviral strategies (Q35658152) (← links)
- Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges (Q35929084) (← links)